# LIBRETTO-431 (NCT04194944)

> A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04194944
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Eli Lilly and Company
- Conditions: Non-Small Cell Lung Cancer
- Interventions: Selpercatinib; Carboplatin; Cisplatin; Pemetrexed; Pembrolizumab
- Enrollment: 261
- Primary outcome: Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) (With Pembrolizumab)
- Primary outcome: PFS by BICR (With or Without Pembrolizumab)

## Commentary we found

- X threads: 46
- Podcasts: 22
- YouTube: 20

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=libretto-431-nct04194944

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04194944", "email": "<work email>"}; the inbox owner confirms by the emailed link.